Lipoprotein(a): The underestimated cardiovascular risk factor

Heart

Volumn 100, Issue 7, 2014, Pages 534-535

  Thompson, Gilbert R ^a   Seed, Mary ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR;

CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; EDITORIAL; HEART INFARCTION; HUMAN; LIPID ANALYSIS; LIPID METABOLISM; LIPOPROTEIN APHERESIS SYSTEM; PRIORITY JOURNAL; PROTEIN DETERMINATION; RISK FACTOR; RISK REDUCTION; STRUCTURE ANALYSIS;

APHERESIS; ATHEROSCLEROSIS; IMMUNOASSAY; LP(A); THROMBOSIS;

CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEIN(A); RISK FACTORS;

EID: 84896543027     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2013-304902     Document Type: Editorial

References (18)

1. Berg K, Mohr J. Genetics of the Lp system. Acta Genet 1963;13:349-60.
2. Kronenberg F, Utermann G. Lipoprotein (a): resurrected by genetics. J Intern Med 2013;273: 6-30.
3. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein (a) as a cardiovascular risk factor: current status. Eur Ht J 2010;31:2844-53.
4. Frishman ME, Ikewaki K, Trenkwalder E, et al. In vivo stable-isotope study suggests intracellular assembly of lipoprotein (a). Atherosclerosis 2012;225: 322-7.
5. Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302: 412-23.
6. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009;301: 2331-9.
7. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009;361: 2518-28.
8. Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Eng J Med 2013;368:503-12.
9. Greif M, Arnold T, von Ziegler F, et al. Lipoprotein (a) is independently correlated with coronary artery calcification. Eur J Clin Med 2013;24:75-9.
10. Qin SY, Liu J, Jiang HX, et al. Association between baseline lipoprotein (a) levels and restenosis after coronary stenting: meta-analysis of 9 cohort studies. Atherosclerosis 2013;227:360-6.
11. Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol 2013;61:1146-56.
12. Albers JJ, Slee A, O'Brien KD, et al. Relationship of Apolipoproteins A-1 and B, and Lipoprotein (a) to Cardiovascular Outcomes in the AIM-HIGH Trial. J Am Coll Cardiol 2013;62:1575-9.
13. Marcovina SM, Albers JJ, Gabel B, et al. Effect of the number of apoprotein(a) Kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem 1995;41:246-55.
14. Marcovina SM, Albers JJ, Scanu AM, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem 2000;46:1956-67.
15. Kulkarni KR, Garber DW, Marcovina SM, et al. Quantification of cholesterol in all lipoprotein classes by the VAP-II method. J Lipid Res 1994;35: 159-68. (Pubitemid 24028002)
16. Jaeger BR, Richter Y, Nagel D, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009;6:229-39.
17. Safarova MS, Ezhov MV, Afanasieva OI, et al. Effect of specific lipoprotein (a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler Suppl 2013;14;93-9.
18. Kolski B, Tsimikas S. Emerging therapeutic agents to lower lipoprotein (a) levels. Curr Opin Lipidol 2012;23:560-8.